Suscripción a Biblioteca: Guest
Portal Digitalde Biblioteca Digital eLibros Revistas Referencias y Libros de Ponencias Colecciones
Critical Reviews™ in Oncogenesis
SJR: 0.631 SNIP: 0.503 CiteScore™: 2

ISSN Imprimir: 0893-9675
ISSN En Línea: 2162-6448

Critical Reviews™ in Oncogenesis

DOI: 10.1615/CritRevOncog.v20.i5-6.170
pages 485-508

Emerging Receptor Tyrosine Kinase Drug Targets: Implications for Antibody-Based Therapies for Oncology and Immunologic Disorders

Theresa M. LaVallee
Kolltan Pharmaceuticals, Inc., New Haven, CT
Diego Alvarado
Kolltan Pharmaceuticals, Inc., New Haven, CT
Andrew J. Garton
Kolltan Pharmaceuticals, Inc., New Haven, CT
E. Sergio Trombetta
Kolltan Pharmaceuticals, Inc., New Haven, CT
Richard Gedrich
Kolltan Pharmaceuticals, Inc., New Haven, CT
Gerald McMahon
Kolltan Pharmaceuticals, Inc., New Haven, CT

SINOPSIS

Protein kinases play a critical regulatory role in essentially every aspect of cell biology. Of the 518 known kinases, the most successful class for drug targeting is the receptor tyrosine kinase (RTK) family consisting of 58 distinct and diverse members. RTKs regulate a broad range of cellular functions, including proliferation, differentiation, survival, and apoptosis and have been intensively studied in development and cancer. Targeting of RTKs has resulted in many marketed small molecule and antibody-based drugs in a number of different solid tumors and hematological malignancies, and more recently in inflammatory diseases such as idiopathic pulmonary fibrosis. In this review, we discuss some of the RTKs in cancer in which drugs targeting the ErbB family (EGFR, HER2, and ErbB3) and KIT have had meaningful clinical benefit to cancer patients, RTKs' emerging role in regulating innate immunity, and the potential to explore targeting RTKs outside of oncology.


Articles with similar content:

The Ideological Frame of the Genetic Basis of Cancer: The Important Role of miRNAs
Critical Reviews™ in Oncogenesis, Vol.22, 2017, issue 3-4
Vassilis Zoumpourlis, Ioannis Christodoulou, Eleni Skourti, Maria Goulielmaki, Spiros Vlahopoulos
Targeting the Insulin-like Growth Factor Receptor: Developing Biomarkers from Gene Expression Profiling
Critical Reviews™ in Oncogenesis, Vol.17, 2012, issue 2
David N. Boone, Adrian V. Lee
RKIP-Mediated Chemo-Immunosensitization of Resistant Cancer Cells via Disruption of the NF-κB/Snail/YY1/RKIP Resistance-Driver Loop
Critical Reviews™ in Oncogenesis, Vol.19, 2014, issue 6
Benjamin Bonavida
Notch Signaling: A Potential Therapeutic Target for Hematologic Malignancies
Critical Reviews™ in Eukaryotic Gene Expression, Vol.26, 2016, issue 3
Mei Lin, Keyu Yuan, Lingbao Gao, Wei Ding
Interleukin 35−Producing B Cells (i35-Breg): A New Mediator of Regulatory B-Cell Functions in CNS Autoimmune Diseases
Critical Reviews™ in Immunology, Vol.35, 2015, issue 1
Charles E. Egwuagu, Cheng-Rong Yu